Regresar

Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases

Abstract:

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the clinical benefits and harms of interleukin-receptor antagonists and tumor necrosis factor (TNF) inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases. To determine whether interleukin-receptor antagonists or TNF inhibitors, provided to people both with and without pre-existing cardiovascular disease, are: useful in preventing adverse cardiovascular outcomes; and safe.